FDA Outlines AI Lifecycle Management Approach
Summary
On July 25, 2024, Food and Drug Administration’s (FDA) Digital Health Center of Excellence (DHCoE) published a blog post that describes how lifecycle management can be used to address the unique challenges of generative AI in health care. The AI lifecycle identifies key activities and systemic methods to manage AI products, which FDA recommends that manufacturers use as a guide to help assess and develop standards, tools and best practices.
Impacted Sectors
Additional Information
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.